The classification system proposed for seizures associated with neurocysticercosis is both innovative and clinically insightful. However, it made me wonder about its applicability in regions where access to advanced imaging modalities like MRI or CT is limited. In such settings, could this framework be adapted using more accessible diagnostic tools or clinical criteria to approximate cyst stages?
Exploring alternative methods, such as biomarkers or simplified imaging protocols, might make this approach more feasible for healthcare providers in resource-limited areas while retaining its diagnostic value. I’d be interested to hear the authors’ thoughts on potential pathways to expand the system’s usability.